No one wants to talk about constipation. Except AstraZeneca. On national television. To the tune of almost $10 million in media spending since late June, according to real-time TV ad tracker iSpot.tv.
Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $80 million from a syndicate that includes a group of high-profile crossover investors.
AstraZeneca has filled the vacancy at the head of its R&D organization. Sean Bohen is set to take up the post next month after being persuaded to swap a position at the heart of early-stage R&D at Genentech for a chance to guide AstraZeneca's late-phase hopefuls toward approval.
AstraZeneca has struck its fourth immuno-oncology deal in as many weeks. The latest deal in the flurry of activity sees AstraZeneca hook up with Peregrine Pharmaceuticals to add another study to the burgeoning list of PD-L1 checkpoint inhibitor combination trials.
India's Controller of Patents has turned down a compulsory license application by Lee Pharma to make a version of AstraZeneca's Onglyza, citing competing substitutes already in the market and patent terms, the Economic Times reported.
We've heard pharma's latest numbers on individual product sales. We know how each company's drugs stack up internally. But how are the top-prescribed brands doing in the overall industry horse race?
Australian smart inhaler player Adherium has raised AU$35 million ($25.8 million) in an IPO that's supported by its big pharma partner AstraZeneca. The biopharma committed to kicking in $3 million of the IPO fundraising, which was reported 2x oversubscribed by investors.
MedImmune on Monday announced a development deal worth up to $727 million--$27 million upfront--to acquire exclusive rights to Inovio Pharmaceuticals' HPV cancer vaccine INO-3112 and to develop additional cancer vaccine candidates.
AstraZeneca's big MedImmune subsidiary has nailed down its third pact in 5 days, inking a collaboration with Inovio Pharmaceuticals on a cancer vaccine designed to generate a tumor-specific T cell response. MedImmune is handing over a $27.5 million upfront and up to $700 million in milestones for the deal while agreeing to also cover the research tab.
For an asthmatic who reaches for their inhaler to discover it contains no drug could be troubling, but that is the chance in Denmark, where AstraZeneca is recalling potentially empty devices.